Acadia Healthcare (ACHC) 10-Q 1 Aug 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		92,867,210

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 77,167	$ 100,073
Accounts receivable, net	389,374	361,451
Other current assets	178,673	134,476
Total current assets	645,214	596,000
Property and equipment, net	2,497,856	2,266,610
Goodwill	2,261,395	2,225,962
Intangible assets, net	73,348	73,278
Deferred tax assets	2,741	6,658
Operating lease right-of-use assets	123,273	117,780
Other assets	74,225	72,553
Total assets	5,678,052	5,358,841
Current liabilities:
Current portion of long-term debt	66,574	29,219
Accounts payable	159,520	156,132
Accrued salaries and benefits	134,503	141,901
Current portion of operating lease liabilities	27,010	26,268
Other accrued liabilities	158,915	532,261
Total current liabilities	546,522	885,781
Long-term debt	1,774,556	1,342,548
Deferred tax liabilities	37,031	1,931
Operating lease liabilities	104,706	100,808
Other liabilities	150,641	140,113
Total liabilities	2,613,456	2,471,181
Redeemable noncontrolling interests	111,878	105,686
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 91,680,774 and 91,263,989 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	917	913
Additional paid-in capital	2,665,215	2,649,340
Retained earnings	286,586	131,721
Total equity	2,952,718	2,781,974
Total liabilities and equity	$ 5,678,052	$ 5,358,841

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	91,680,774	91,263,989
Common stock, shares outstanding	91,680,774	91,263,989

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 796,040	$ 731,337	$ 1,564,091	$ 1,435,604
Salaries, wages and benefits (including equity-based compensation expense of $8,869, $7,348, $17,547 and $14,977, respectively)	419,757	386,633	837,280	777,810
Professional fees	48,050	43,803	93,738	84,928
Supplies	27,878	26,144	54,530	52,165
Rents and leases	11,889	11,725	23,752	23,149
Other operating expenses	109,690	95,912	210,763	186,750
Depreciation and amortization	36,066	32,012	72,413	63,581
Interest expense, net	29,159	20,910	56,373	40,909
Loss on impairment	1,000	8,694	1,000	8,694
Transaction, legal and other costs	6,091	9,074	8,938	15,545
Total expenses	689,580	634,907	1,358,787	1,253,531
Income before income taxes	106,460	96,430	205,304	182,073
Provision for income taxes	25,643	22,881	45,717	41,966
Net income	80,817	73,549	159,587	140,107
Net income attributable to noncontrolling interests	(2,335)	(1,250)	(4,722)	(1,793)
Net income attributable to Acadia Healthcare Company, Inc.	$ 78,482	$ 72,299	$ 154,865	$ 138,314
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.86	$ 0.79	$ 1.69	$ 1.53
Diluted	$ 0.85	$ 0.79	$ 1.68	$ 1.51
Weighted-average shares outstanding:
Basic	91,628	91,044	91,495	90,691
Diluted	92,043	91,546	92,051	91,640

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Equity-based compensation expense	$ 8,869	$ 7,348	$ 17,547	$ 14,977

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2022	$ 2,812,727	$ 899	$ 2,658,440	$ 153,388
Balance, shares at Dec. 31, 2022		89,914,000
Common stock issued under stock incentive plans	1,203	$ 11	1,192
Common stock issued under stock incentive plans, shares		1,039,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(48,874)		(48,874)
Equity-based compensation expense	7,629		7,629
Other	902		902
Net Income (Loss)	66,015			66,015
Balance at Mar. 31, 2023	2,839,602	$ 910	2,619,289	219,403
Balance, shares at Mar. 31, 2023		90,953,000
Balance at Dec. 31, 2022	2,812,727	$ 899	2,658,440	153,388
Balance, shares at Dec. 31, 2022		89,914,000
Net Income (Loss)	138,314
Balance at Jun. 30, 2023	2,921,016	$ 911	2,628,403	291,702
Balance, shares at Jun. 30, 2023		91,129,000
Balance at Dec. 31, 2022	$ 2,812,727	$ 899	2,658,440	153,388
Balance, shares at Dec. 31, 2022		89,914,000
Common stock issued under stock incentive plans, shares	198,527
Balance at Dec. 31, 2023	$ 2,781,974	$ 913	2,649,340	131,721
Balance, shares at Dec. 31, 2023	91,263,989	91,264,000
Balance at Mar. 31, 2023	$ 2,839,602	$ 910	2,619,289	219,403
Balance, shares at Mar. 31, 2023		90,953,000
Common stock issued under stock incentive plans	3,784	$ 1	3,783
Common stock issued under stock incentive plans, shares		176,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(2,017)		(2,017)
Equity-based compensation expense	7,348		7,348
Net Income (Loss)	72,299			72,299
Balance at Jun. 30, 2023	2,921,016	$ 911	2,628,403	291,702
Balance, shares at Jun. 30, 2023		91,129,000
Common stock issued under stock incentive plans	1,554	$ 1	1,553
Common stock issued under stock incentive plans, shares		76,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(843)		(843)
Equity-based compensation expense	8,163		8,163
Other	382		382
Net Income (Loss)	(217,710)			(217,710)
Balance at Sep. 30, 2023	2,712,562	$ 912	2,637,658	73,992
Balance, shares at Sep. 30, 2023		91,205,000
Common stock issued under stock incentive plans	1,656	$ 1	1,655
Common stock issued under stock incentive plans, shares		59,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(798)		(798)
Equity-based compensation expense	9,149		9,149
Other	1,676		1,676
Net Income (Loss)	57,729			57,729
Balance at Dec. 31, 2023	$ 2,781,974	$ 913	2,649,340	131,721
Balance, shares at Dec. 31, 2023	91,263,989	91,264,000
Common stock issued under stock incentive plans	$ 4,102	$ 3	4,099
Common stock issued under stock incentive plans, shares		310,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(5,115)		(5,115)
Equity-based compensation expense	8,678		8,678
Net Income (Loss)	76,383			76,383
Balance at Mar. 31, 2024	2,866,022	$ 916	2,657,002	208,104
Balance, shares at Mar. 31, 2024		91,574,000
Balance at Dec. 31, 2023	$ 2,781,974	$ 913	2,649,340	131,721
Balance, shares at Dec. 31, 2023	91,263,989	91,264,000
Common stock issued under stock incentive plans, shares	121,468
Net Income (Loss)	$ 154,865
Balance at Jun. 30, 2024	$ 2,952,718	$ 917	2,665,215	286,586
Balance, shares at Jun. 30, 2024	91,680,774	91,681,000
Balance at Mar. 31, 2024	$ 2,866,022	$ 916	2,657,002	208,104
Balance, shares at Mar. 31, 2024		91,574,000
Common stock issued under stock incentive plans	1,478	$ 1	1,477
Common stock issued under stock incentive plans, shares		107,000
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(2,133)		(2,133)
Equity-based compensation expense	8,869		8,869
Net Income (Loss)	78,482			78,482
Balance at Jun. 30, 2024	$ 2,952,718	$ 917	$ 2,665,215	$ 286,586
Balance, shares at Jun. 30, 2024	91,680,774	91,681,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net income	$ 159,587	$ 140,107
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization	72,413	63,581
Amortization of debt issuance costs	2,034	1,651
Equity-based compensation expense	17,547	14,977
Deferred income taxes	39,017	347
Loss on impairment	1,000	8,694
Other	(3,942)	1,086
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(26,114)	(23,397)
Other current assets	(14,182)	(8,743)
Other assets	842	(322)
Accounts payable and other accrued liabilities	(399,619)	21,518
Accrued salaries and benefits	(8,525)	(13,889)
Other liabilities	9,805	2,568
Net cash (used in) provided by operating activities	(150,137)	208,178
Investing activities:
Cash paid for acquisitions, net of cash acquired	(50,722)
Cash paid for capital expenditures	(296,652)	(157,359)
Proceeds from sale of property and equipment	10,209	621
Other	(2,933)	(940)
Net cash used in investing activities	(340,098)	(157,678)
Financing activities:
Borrowings on long-term debt	350,000
Principal payments on revolving credit facility	(15,000)	(20,000)
Principal payments on long-term debt	(25,605)	(10,625)
Payment of debt issuance costs	(1,518)
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	(1,668)	(45,904)
Contributions from noncontrolling partners in joint ventures	2,970	2,516
Distributions to noncontrolling partners in joint ventures	(1,500)	(1,983)
Other	(350)	20
Net cash provided by (used in) financing activities	467,329	(35,976)
Net (decrease) increase in cash and cash equivalents	(22,906)	14,524
Cash and cash equivalents at beginning of the period	100,073	97,649
Cash and cash equivalents at end of the period	77,167	112,173
Effect of acquisitions:
Assets acquired, excluding cash	55,678
Liabilities assumed	(3,456)
Contingent consideration issued in connection with an acquisition	(1,500)
Cash paid for acquisitions, net of cash acquired	50,722
New Credit Facility [Member]
Financing activities:
Borrowings on revolving credit facility	$ 160,000	$ 40,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 78,482	$ 76,383	$ 57,729	$ (217,710)	$ 72,299	$ 66,015	$ 154,865	$ 138,314

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Title	directors or officers
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Description of Business Acadia Healthcare Company, Inc. (the “Company”) develops and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (“CTCs”), residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the United States (“U.S.”) and Puerto Rico. At June 30, 2024, the Company operated 258 behavioral healthcare facilities with approximately 11,400 beds in 38 states and Puerto Rico. Basis of Presentation The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of the Company’s financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2024. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to the prior year to conform to the current year presentation.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2024
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Standards	2. Recently Issued Accounting Standards In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-07 Segment Reporting (Topic 280) (“ASU 2023-07”) “ Improvements to Reportable Segment Disclosures. ” ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023, and the interim periods within the fiscal years beginning after December 15, 2024, with early adoption permitted and applied retrospectively. The Company is currently evaluating the impact of ASU 2023-07 on the Company's consolidated financial statements. In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) (“ASU 2023-09”) “ Improvements to Income Tax Disclosures. ” ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. This guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2023-09 on the Company’s consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2024
Revenue From Contract With Customer [Abstract]
Revenue	3. Revenue Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract. Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms. As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as its patients typically are under no obligation to remain admitted in the Company’s facilities. The Company disaggregates revenue from contracts with customers by service type and by payor. The Company’s facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers. Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists. Specialty treatment facilities . Specialty treatment facilities include residential recovery facilities and eating disorder facilities. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care. Comprehensive treatment centers . CTCs specialize in providing medication-assisted treatment in an outpatient setting to Residential treatment centers . Residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. The table below presents total revenue attributed to each category (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Acute inpatient psychiatric facilities $ 423,383 $ 369,415 $ 829,805 $ 731,226 Specialty treatment facilities 151,049 156,908 294,881 304,211 Comprehensive treatment centers 134,643 123,472 266,810 238,973 Residential treatment centers 86,965 81,542 172,595 161,194 Revenue $ 796,040 $ 731,337 $ 1,564,091 $ 1,435,604 The Company receives payments from the following sources for services rendered in its facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”) and other programs; and (iv) individual patients and clients. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidated statements of operations. Bad debt expense for the three and six months ended June 30, 2024 and 2023 was not significant. The following table presents the Company’s revenue by payor type and as a percentage of revenue (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Amount % Amount % Amount % Amount % Commercial $ 209,636 26.3 % $ 209,383 28.6 % $ 405,653 25.9 % $ 413,002 28.8 % Medicare 111,708 14.0 % 109,845 15.0 % 221,096 14.1 % 218,485 15.2 % Medicaid 452,338 56.9 % 391,963 53.6 % 888,760 56.9 % 756,269 52.7 % Self-Pay 13,513 1.7 % 15,804 2.2 % 29,940 1.9 % 36,502 2.5 % Other 8,845 1.1 % 4,342 0.6 % 18,642 1.2 % 11,346 0.8 % Revenue $ 796,040 100.0 % $ 731,337 100.0 % $ 1,564,091 100.0 % $ 1,435,604 100.0 %

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	4. Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2024 and 2023 (in thousands, except per share amounts): Three Months Ended Six Months Ended 2024 2023 2024 2023 Numerator: Net income attributable to Acadia Healthcare Company, Inc. $ 78,482 $ 72,299 $ 154,865 $ 138,314 Denominator: Weighted average shares outstanding for basic earnings per share 91,628 91,044 91,495 90,691 Effects of dilutive instruments 415 502 556 949 Shares used in computing diluted earnings per common share 92,043 91,546 92,051 91,640 Earnings per share attributable to Acadia Healthcare Basic $ 0.86 $ 0.79 $ 1.69 $ 1.53 Diluted $ 0.85 $ 0.79 $ 1.68 $ 1.51 Approximately 0.8 million and 0.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended June 30, 2024 and 2023, respectively, because their effect would have been anti-dilutive. Approximately 0.6 million and 0.5 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the six months ended June 30, 2024 and 2023 , respectively, because their effect would have been anti-dilutive.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Acquisitions	5. Acquisitions The Company’s acquisition strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations. On February 22, 2024, the Company acquired substantially all of the assets of Turning Point Centers (“Turning Point”), a 76-bed specialty provider of substance use disorder and primary mental health treatment services that supports the Salt Lake City, Utah, metropolitan market. Turning Point provides a full continuum of treatment services, including residential, partial hospitalization and intensive outpatient services. Goodwill The changes in goodwill are as follows (in thousands): Balance at January 1, 2023 $ 2,222,805 Increase from acquisitions 337 Increase from contributions of redeemable noncontrolling interests 2,820 Balance at December 31, 2023 2,225,962 Increase from acquisitions 35,433 Balance at June 30, 2024 $ 2,261,395

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2024
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Current Assets	6. Other Current Assets Other current assets consisted of the following (in thousands): June 30, December 31, Insurance receivable – current portion $ 54,096 $ 33,579 Income taxes receivable 37,133 12,416 Prepaid expenses 31,930 36,085 Other receivables 24,005 22,084 Workers’ compensation deposits – current portion 12,000 12,000 Assets held for sale 11,865 11,496 Inventory 5,988 5,300 Other 1,656 1,516 Other current assets $ 178,673 $ 134,476

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property Plant And Equipment [Abstract]
Property and Equipment	7. Property and Equipment Property and equipment consisted of the following (in thousands): June 30, December 31, Land $ 195,759 $ 183,347 Building and improvements 2,105,463 2,064,353 Equipment 402,307 365,826 Construction in progress 626,279 420,430 3,329,808 3,033,956 Less: accumulated depreciation ( 831,952 ) ( 767,346 ) Property and equipment, net $ 2,497,856 $ 2,266,610 During the three months ended June 30, 2024, the Company recorded a non-cash property impairment charge of $ 1.0 million related to certain closed facilities, which is included in loss on impairment in the condensed consolidated statements of income. During the three months ended June 30, 2023, the Company recorded a non-cash property impairment charge of $ 2.0 million and a non-cash operating lease right-of-use asset impairment charge of $ 2.0 million related to the closure of certain facilities, which is included in loss on impairment in the condensed consolidated statements of income. The Company has recorded assets held for sale within other current assets on the consolidated balance sheets for closed properties actively marketed of $ 11.9 million and $ 11.5 million at June 30, 2024 and December 31, 2023 , respectively.

Other Intangible Assets

Other Intangible Assets	6 Months Ended
	Jun. 30, 2024
Goodwill And Intangible Assets Disclosure [Abstract]
Other Intangible Assets	8. Other Intangible Assets Other identifiable intangible assets and related accumulated amortization consisted of the following (in thousands): Gross Carrying Amount Accumulated Amortization June 30, December 31, June 30, December 31, Intangible assets subject to amortization: Non-compete agreements $ 1,131 $ 1,131 $ ( 1,131 ) $ ( 1,131 ) Intangible assets not subject to amortization: Licenses and accreditations 11,688 11,681 — — Trade names 42,588 42,588 — — Certificates of need 19,072 19,009 — — 73,348 73,278 — — Total $ 74,479 $ 74,409 $ ( 1,131 ) $ ( 1,131 ) All of the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificates of need have indefinite lives and are, therefore, not subject to amortization. During the three months ended June 30, 2023, the Company recorded a non-cash indefinite-lived intangible asset impairment charge of $ 4.7 million related to the closure of certain facilities, which is included in loss on impairment in the condensed consolidated statements of income.

The CARES Act

The CARES Act	6 Months Ended
	Jun. 30, 2024
Extraordinary And Unusual Items [Abstract]
The CARES Act	9. The CARES Act As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $ 100 billion of relief to eligible healthcare providers. The Company accounts for government grants by analogizing to the grant model in accordance with International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance , and as such, has recognized income from grants in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. The Company recognizes grants once both of the following conditions are met: (i) the Company is able to comply with the relevant terms and conditions of the grant and (ii) the grant will be received. The Company has participated in certain relief programs offered through the CARES Act, including receipt of funds relating to the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund, and the American Rescue Plan (“ARP”) Rural Payments for Hospitals. During the year ended December 31, 2023, the Company recorded $ 6.4 million of income from provider relief fund related to ARP funds received and repaid the remaining balance of ARP funds to eliminate the liability. Healthcare providers were required to sign an attestation confirming receipt of the PHSSE Fund amounts and agree to the terms and conditions of payment. Under the terms and conditions for receipt of the payment, the Company was allowed to use the funds to cover lost revenues and healthcare costs related to the novel coronavirus known as COVID-19 ( “COVID-19”), and the Company was required to properly and fully document the use of these funds to the U.S. Department of Health and Human Services. The reporting of these funds is subject to future audit for compliance with the terms and conditions. The Company recognized PHSSE Fund amounts to the extent it had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions.

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2024
Other Liabilities Disclosure [Abstract]
Other Accrued Liabilities	11. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued expenses $ 69,364 $ 80,733 Insurance liability – current portion 41,986 12,486 Accrued interest 18,158 18,046 Accrued property taxes 9,539 7,097 Cost report payable 4,293 9,265 Contract liabilities 1,801 2,165 Finance lease liabilities 990 990 Accrued Desert Hills settlement — 393,696 Other 12,784 7,783 Other accrued liabilities $ 158,915 $ 532,261

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt	12. Long-Term Debt Long-term debt consisted of the following (in thousands): June 30, December 31, Credit Facility: Term Loan A $ 701,583 $ 377,188 Revolving Line of Credit 225,000 80,000 5.500 % Senior Notes due 2028 450,000 450,000 5.000 % Senior Notes due 2029 475,000 475,000 Less: unamortized debt issuance costs, discount and ( 10,453 ) ( 10,421 ) 1,841,130 1,371,767 Less: current portion ( 66,574 ) ( 29,219 ) Long-term debt $ 1,774,556 $ 1,342,548 Credit Facility On March 17, 2021, the Company entered into a credit agreement (as amended the “Credit Facility”), which provides for a $ 600.0 million senior secured revolving credit facility (the “Revolving Facility”) and a senior secured term loan facility in an initial principal amount of $ 425.0 million (as increased by the Incremental Term Loans (as defined below), the “Term Loan Facility”), each maturing on March 17, 2026 . The Revolving Facility further provides for a $ 20.0 million subfacility for the issuance of letters of credit. On March 30, 2023, the Company entered into Amendment No. 1 to the Credit Facility (the “First Amendment”), which replaced the London Interbank Offered Rate (“LIBOR”), as the reference rate applicable to borrowings under the Credit Facility with the Secured Overnight Financing Rate as determined for a term of, at the Company’s option, one, three or six months, plus an adjustment of 0.10 % (“Adjusted Term SOFR”). After giving effect to the First Amendment, borrowings under the Credit Facility bear interest at a rate equal to, at the Company’s option, either (i) Adjusted Term SOFR plus a margin ranging from 1.375 % to 2.250 % or (ii) a base rate plus a margin ranging from 0.375 % to 1.250 %, in each case, depending on the consolidated total net leverage ratio. In addition, an unused fee that varies according to the consolidated total net leverage ratio of the Company ranging from 0.200 % to 0.350 % is payable quarterly in arrears based on the average daily undrawn portion of the commitments in respect of the Revolving Facility. On January 18, 2024, the Company entered into Amendment No. 2 to the Credit Facility (the “Second Amendment”), which provides for the incurrence of additional senior secured term loans in an aggregate principal amount of $ 350.0 million (the “Incremental Term Loans”). Such Incremental Term Loans are structured as an increase of the Term Loan Facility. The maturity date, the leverage-based pricing grid, mandatory prepayment events and other terms applicable to the Incremental Term Loans are substantially identical to those applicable to the initial $ 425.0 million term loans incurred under the Term Loan Facility. After giving effect to the Incremental Term Loans, the Credit Facility requires quarterly principal repayments for the Term Loan Facility of approximately $ 15.4 million for each quarter ending from September 30, 2024 to March 31, 2025 and $ 20.5 million for each quarter ending from June 30, 2025 to December 31, 2025. The remaining outstanding principal balance of the Term Loan Facility is due on the maturity date of March 17, 2026 . The Company has the ability to increase the amount of the Credit Facility, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $ 480.0 million and an amount equal to 100 % of the consolidated EBITDA of the Company at the time of determination (the “Incremental Fixed Basket”) and (ii) additional amounts that would not cause the Company’s consolidated senior secured net leverage ratio to exceed 3.5 to 1.0 (the “Incremental Ratio Basket”). The Incremental Term Loans were incurred in reliance on the Incremental Ratio Basket, leaving the full amount of the Incremental Fixed Basket available for any future Incremental Facilities. Subject to certain exceptions, substantially all of the Company’s existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of the Company’s obligations under the Credit Facility. The Company and such guarantor subsidiaries have granted a security interest in substantially all personal property assets as collateral for the obligations under the Credit Facility. The Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 4.5 to 1.0 (which may be increased to 5.0 to 1.0 for a period of up to four consecutive fiscal quarters following the consummation of certain material acquisitions) and an interest coverage ratio of at least 3.0 to 1.0. The Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Credit Facility may be accelerated, the lenders’ commitments terminated, and/or the lenders may exercise collateral remedies. At June 30, 2024, the Company was in compliance with all financial covenants. During the six months ended June 30, 2024, the Company borrowed $ 160.0 million on the Revolving Facility and repaid $ 15.0 million of the balance outstanding. During the six months ended June 30, 2023, the Company borrowed $ 40.0 million on the Revolving Facility and repaid $ 20.0 million of the balance outstanding. The Company had $ 371.5 million of availability under the Revolving Facility and had standby letters of credit outstanding of $ 3.5 million related to security for the payment of claims required by its workers’ compensation insurance program at June 30, 2024. Senior Notes 5.500% Senior Notes due 2028 On June 24, 2020, the Company issued $ 450.0 million of 5.500 % Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021 . 5.000% Senior Notes due 2029 On October 14, 2020, the Company issued $ 475.0 million of 5.000 % Senior Notes due 2029 (the “5.000% Senior Notes”). The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021. The indentures governing the 5.500% Senior Notes and the 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets. The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Credit Facility. The guarantees are full and unconditional and joint and several. The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

Noncontrolling Interests

Noncontrolling Interests	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interests	13. Noncontrolling Interests Noncontrolling interests in the consolidated financial statements represent the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At June 30, 2024 , the Company operated ten facilities through non-wholly owned subsidiaries. The Company owns between approximately 65 % and 87 % of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions. The Company consolidates the operations of each facility based on its status as primary beneficiary, as further discussed in Note 14 – Variable Interest Entities. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control. The components of redeemable noncontrolling interests are as follows (in thousands): Balance at January 1, 2023 $ 88,257 Contributions from noncontrolling partners in joint ventures 16,530 Net income attributable to noncontrolling interests 6,006 Distributions to noncontrolling partners in joint ventures ( 5,107 ) Balance at December 31, 2023 105,686 Contributions from noncontrolling partners in joint ventures 2,970 Net income attributable to noncontrolling interests 4,722 Distributions to noncontrolling partners in joint ventures ( 1,500 ) Balance at June 30, 2024 $ 111,878

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2024
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable Interest Entities	14. Variable Interest Entities For legal entities where the Company has a financial relationship, the Company evaluates whether it has a variable interest and determines if the entity is considered a variable interest entity (“VIE”). If the Company concludes an entity is a VIE and the Company is the primary beneficiary, the entity is consolidated. The primary beneficiary analysis is a qualitative analysis based on power and benefits. A reporting entity has a controlling financial interest in a VIE and must consolidate the VIE if it has both power and benefits. It must have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE. At June 30, 2024 , the Company operated ten facilities through non-wholly owned subsidiaries. The Company owns between approximately 65 % and 87 % of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The Company manages each of these facilities, is responsible for the day-to-day operations and, therefore, has the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These activities include, but are not limited to, behavioral healthcare services, human resource and employment-related decisions, marketing and finance. The terms of the agreements governing each of the Company’s VIEs prohibit the Company from using the assets of each VIE to satisfy the obligations of other entities. Consolidated assets at June 30, 2024 and December 31, 2023 include total assets of variable interest entities of $ 729.3 million and $ 597.8 million, respectively, which cannot be used to settle the obligations of other entities. Consolidated liabilities at June 30, 2024 and December 31, 2023 include total liabilities of variable interest entities of $ 33.4 million and $ 27.0 million, respectively. The consolidated VIEs assets and liabilities in the Company’s condensed consolidated balance sheets are shown below (in thousands): June 30, December 31, Cash and cash equivalents $ 74,099 $ 55,149 Accounts receivable, net 40,026 34,910 Other current assets 2,407 2,193 Total current assets 116,532 92,252 Property and equipment, net 541,961 438,965 Goodwill 42,384 42,384 Intangible assets, net 18,333 18,295 Operating lease right-of-use assets 10,064 5,948 Total assets $ 729,274 $ 597,844 Accounts payable $ 10,322 $ 8,235 Accrued salaries and benefits 9,990 9,909 Current portion of operating lease liabilities 573 273 Other accrued liabilities 2,444 2,385 Total current liabilities 23,329 20,802 Operating lease liabilities 10,056 6,160 Total liabilities $ 33,385 $ 26,962

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2024
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity-Based Compensation	15. Equity-Based Compensation Equity Incentive Plans The Company issues stock-based awards, including stock options, restricted stock units and performance stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At June 30, 2024, a maximum of 12,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock units and performance stock units or other share-based compensation under the Equity Incentive Plan, of which 2,068,284 were available for future grant. Stock options may be granted for terms of up to ten years . The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25 % or 33 % each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the most recent trading date prior to the date of grant. The Company recognized $ 8.9 million and $ 7.3 million in equity-based compensation expense for the three months ended June 30, 2024 and 2023 , respectively, and $ 17.5 million and $ 15.0 million for the six months ended June 30, 2024 and 2023, respectively. Stock compensation expense for the six months ended June 30, 2024 and 2023 is impacted by forfeiture adjustments and performance stock unit adjustments based on actual performance compared to vesting targets. At June 30, 2024, there was $ 89.1 million of unrecognized compensation expense related to unvested options, restricted stock units and performance stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.3 years. The Company recognized a deferred income tax benefit of $ 2.4 million and $ 2.0 million for the three months ended June 30, 2024 and 2023, respectively, and $ 4.8 million and $ 4.1 million for the six months ended June 30, 2024 and 2023, respectively, related to equity-based compensation expense. Stock Options Stock option activity during 2023 and 2024 was as follows: Number Weighted Weighted Aggregate Options outstanding at January 1, 2023 979,277 $ 46.27 Options granted 296,340 78.94 Options exercised ( 198,527 ) 41.29 Options cancelled ( 140,545 ) 55.95 Options outstanding at December 31, 2023 936,545 56.21 Options granted 3,000 78.59 Options exercised ( 121,468 ) 45.94 Options cancelled ( 45,560 ) 67.12 Options outstanding at June 30, 2024 772,517 $ 57.27 6.85 $ 10,819 Options exercisable at June 30, 2024 422,652 $ 48.06 5.80 $ 8,872 Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2024 and year ended December 31, 2023: June 30, December 31, Weighted average grant-date fair value of options $ 28.34 $ 30.99 Risk-free interest rate 4.4 % 4.2 % Expected volatility 33 % 37 % Expected life (in years) 4.7 5.0 The Company’s estimate of expected volatility for stock options is based upon the volatility of its stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised. Other Stock-Based Awards Restricted stock unit activity during 2023 and 2024 was as follows: Number of Weighted Unvested at January 1, 2023 1,045,202 $ 54.89 Granted 587,239 76.32 Cancelled ( 198,740 ) 57.21 Vested ( 403,223 ) 50.48 Unvested at December 31, 2023 1,030,478 $ 68.38 Granted 492,602 76.45 Cancelled ( 61,121 ) 70.45 Vested ( 287,340 ) 61.41 Unvested at June 30, 2024 1,174,619 $ 73.36 Performance stock unit activity during 2023 and 2024 was as follows: Number of Weighted Unvested at January 1, 2023 1,273,800 $ 20.69 Granted 177,509 70.98 Performance adjustment 407,825 17.69 Cancelled ( 114,908 ) 69.07 Vested ( 1,408,195 ) 10.60 Unvested at December 31, 2023 336,031 $ 69.35 Granted 75,909 67.85 Performance adjustment ( 9,241 ) 72.99 Cancelled ( 15,723 ) 70.37 Vested ( 98,504 ) 61.52 Unvested at June 30, 2024 288,472 $ 71.45 Restricted stock unit awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock unit awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date. Performance stock units are granted to employees and are subject to Company performance compared to pre-established targets. In addition to Company performance, these performance-based stock units are subject to the continuing service of the employee during the three-year period covered by the awards. The performance conditions for the performance stock units are based on the Company’s achievement of annually established targets for diluted earnings per share, Adjusted EBITDA and/or revenue. The number of shares issuable at the end of the applicable vesting period of performance stock units ranges from 0 % to 200 % of the targeted units based on the Company’s actual performance compared to the targets. The fair values of performance stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions.

Transaction, Legal and Other Co

Transaction, Legal and Other Costs	6 Months Ended
	Jun. 30, 2024
Transaction, Legal and Other Costs [Abstract]
Transaction, Legal and Other Costs	16. Transaction, legal and other costs Transaction, legal and other costs represent costs primarily related to legal, accounting, termination, restructuring, management transition, acquisition and other similar costs. Transaction, legal and other costs comprised the following costs for the three and six months ended June 30, 2024 and 2023 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Legal, accounting and other acquisition-related costs $ 4,085 $ 925 $ 9,323 2,564 Termination and restructuring costs 1,419 1,974 ( 1,981 ) 2,005 Management transition costs 587 6,175 $ 1,596 $ 10,976 $ 6,091 $ 9,074 $ 8,938 $ 15,545

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes The provision for income taxes for the three months ended June 30, 2024 and 2023 reflects effective tax rates of 24.1 % and 23.7 % , respectively, and 22.3 % and 23.0 % for the six months ended June 30, 2024 and 2023, respectively. As the Company continues to monitor the implications of potential tax legislation in each of its jurisdictions, the Company may adjust estimates and record additional amounts for tax assets and liabilities. Any adjustments to the Company’s tax assets and liabilities could materially impact the provision for income taxes and its effective tax rate in the periods in which they are made.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	18. Fair Value Measurements The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments. The carrying amounts and fair values of the Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes at June 30, 2024 and December 31, 2023 were as follows (in thousands): Carrying Amount Fair Value June 30, December 31, June 30, December 31, Credit Facility $ 924,417 $ 455,880 $ 924,417 $ 455,880 5.500% Senior Notes due 2028 $ 445,981 $ 445,539 $ 435,946 $ 436,628 5.000% Senior Notes due 2029 $ 470,732 $ 470,348 $ 446,607 $ 451,534 The Credit Facility, 5.500 % Senior Notes and 5.000 % Senior Notes were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Professional and General Liability The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary providing coverage for up to $ 5.0 million per claim and $ 10.0 million for certain other claims through August 31, 2023 and $ 7.0 million and $ 10.0 million for certain other claims thereafter. The Company has obtained reinsurance coverage from a third-party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $ 75.0 million or $ 70.0 million in the aggregate for certain other claims through August 31, 2023 and $ 78.0 million or $ 75.0 million in the aggregate for certain other claims thereafter. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. Legal Proceedings The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations and violations of the federal False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Desert Hills From October 2018 to August 2020, the Company, its subsidiary Youth and Family Centered Services of New Mexico (“Desert Hills”), and FamilyWorks, a not-for-profit treatment foster care program to which Desert Hills provided management services, including day-to-day administration of the program, via a management services agreement, were among a number of defendants named in five lawsuits (collectively, the “Desert Hills Litigation”) filed in New Mexico State District Court (the “District Court”). These lawsuits each related to abuse by a foster parent, Clarence Garcia, that occurred in foster homes where FamilyWorks had placed children. In 2021, the Company finalized out-of-court settlements for two of the five cases for amounts covered under the Company’s professional liability insurance: Dorsey, as Guardian ad Litem of M.R. v. Clarence Garcia, et al. (the “M.R. case”) , and Higgins, as Guardian ad Litem of J.H. v. Clarence Garcia, et al (the “J.H. case”). While the plaintiffs in those two cases had claims pending against FamilyWorks, and FamilyWorks had raised claims or potential claims against the Company, the parties in each of those cases finalized settlements that resolved all claims between FamilyWorks and the Company. The District Court approved the settlement in the J.H. case on June 10, 2024. The District Court’s approval of the settlement in the M.R. case remains pending, but is expected in the coming months. On July 7, 2023, in connection with one of the lawsuits in the Desert Hills Litigation styled Inman v. Garcia, et al., Case No. D-117-CV-2019-00136 (the “Inman Litigation”), a jury awarded the plaintiff compensatory damages of $ 80.0 million and punitive damages of $ 405.0 million. This award far exceeded the Company’s reasonable expectation based on the previously resolved complaints and far exceeded any precedent for comparable cases. On October 30, 2023, the Company and Desert Hills entered into settlement agreements in connection with the Inman Litigation, as well as two other related cases – Rael v. Garcia, et al., Case No. D-117-CV-2019-00135 and Endicott-Quinones v. Garcia, et al., Case No. D-117-CV-2019-00137 (together with the Inman Litigation, the “Cases”). The settlement agreements for the Cases were approved by the District Court in December 2023 and fully resolve each of the Cases with no admission of liability or wrongdoing by either the Company or Desert Hills. On January 19, 2024, pursuant to the terms of the settlement agreements, the Company paid an aggregate amount of $ 400.0 million in exchange for the release and discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted in the Cases or that may be asserted in the future by the plaintiffs in the Cases. On January 30, 2024, a sixth lawsuit styled CNRAG, Inc. as Legal Guardian of A.C. v. Garcia et al., No. D-117-CV-2024-00045 was filed in the District Court alleging similar claims as the previous five lawsuits in the Desert Hills Litigation. The ward in this sixth lawsuit was referenced in prior criminal charges against Garcia in January 2019; however, prior to this lawsuit, neither the ward nor guardian made contact with the Company about a possible claim. The Company determined that a lawsuit from this plaintiff was unlikely because no claims had ever been asserted and the statute of limitations had expired. Plaintiff’s allegations assert certain claims, which, if true, may toll the statute of limitations. At this time, the Company is not able to quantify the ultimate liability, if any, in connection with this sixth lawsuit. No additional victims are referenced in the prior criminal charges against Garcia. Securities Litigation On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988 , which is pending in the United States District Court for the Middle District of Tennessee. The complaint is brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018. Derivative Actions On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Jacobs, et al., Case No. 3:19-cv-00167 , which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441 , which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 22, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Pfenning v. Jacobs, et al., Case No. 2020-0915-NAC , which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Solak v. Jacobs, et al., Case No. 2021-0163-NAC , which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider selling. Government Investigation In the fall of 2017, the Office of Inspector General (the “OIG”) issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. In June 2023, the State of Nevada issued a subpoena relating to one of the same facilities as part of the same investigation. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company has reached a tentative agreement to resolve the matter and the anticipated financial impact of such resolution is $ 19.9 million and has been recorded within other accrued liabilities on the condensed consolidated balance sheets at June 30, 2024 and December 31, 2023 , respectively.

Revenue (Tables)

Revenue (Tables) - U.S. Facilities [Member]	6 Months Ended
	Jun. 30, 2024
Schedule of Revenue Attributed to Each Category	The table below presents total revenue attributed to each category (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Acute inpatient psychiatric facilities $ 423,383 $ 369,415 $ 829,805 $ 731,226 Specialty treatment facilities 151,049 156,908 294,881 304,211 Comprehensive treatment centers 134,643 123,472 266,810 238,973 Residential treatment centers 86,965 81,542 172,595 161,194 Revenue $ 796,040 $ 731,337 $ 1,564,091 $ 1,435,604
Schedule of Revenue and Percentage Generated by Each Payor Type	The following table presents the Company’s revenue by payor type and as a percentage of revenue (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Amount % Amount % Amount % Amount % Commercial $ 209,636 26.3 % $ 209,383 28.6 % $ 405,653 25.9 % $ 413,002 28.8 % Medicare 111,708 14.0 % 109,845 15.0 % 221,096 14.1 % 218,485 15.2 % Medicaid 452,338 56.9 % 391,963 53.6 % 888,760 56.9 % 756,269 52.7 % Self-Pay 13,513 1.7 % 15,804 2.2 % 29,940 1.9 % 36,502 2.5 % Other 8,845 1.1 % 4,342 0.6 % 18,642 1.2 % 11,346 0.8 % Revenue $ 796,040 100.0 % $ 731,337 100.0 % $ 1,564,091 100.0 % $ 1,435,604 100.0 %

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2024 and 2023 (in thousands, except per share amounts): Three Months Ended Six Months Ended 2024 2023 2024 2023 Numerator: Net income attributable to Acadia Healthcare Company, Inc. $ 78,482 $ 72,299 $ 154,865 $ 138,314 Denominator: Weighted average shares outstanding for basic earnings per share 91,628 91,044 91,495 90,691 Effects of dilutive instruments 415 502 556 949 Shares used in computing diluted earnings per common share 92,043 91,546 92,051 91,640 Earnings per share attributable to Acadia Healthcare Basic $ 0.86 $ 0.79 $ 1.69 $ 1.53 Diluted $ 0.85 $ 0.79 $ 1.68 $ 1.51

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Summary of Changes in Goodwill	The changes in goodwill are as follows (in thousands): Balance at January 1, 2023 $ 2,222,805 Increase from acquisitions 337 Increase from contributions of redeemable noncontrolling interests 2,820 Balance at December 31, 2023 2,225,962 Increase from acquisitions 35,433 Balance at June 30, 2024 $ 2,261,395

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Current Assets	Other current assets consisted of the following (in thousands): June 30, December 31, Insurance receivable – current portion $ 54,096 $ 33,579 Income taxes receivable 37,133 12,416 Prepaid expenses 31,930 36,085 Other receivables 24,005 22,084 Workers’ compensation deposits – current portion 12,000 12,000 Assets held for sale 11,865 11,496 Inventory 5,988 5,300 Other 1,656 1,516 Other current assets $ 178,673 $ 134,476

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following (in thousands): June 30, December 31, Land $ 195,759 $ 183,347 Building and improvements 2,105,463 2,064,353 Equipment 402,307 365,826 Construction in progress 626,279 420,430 3,329,808 3,033,956 Less: accumulated depreciation ( 831,952 ) ( 767,346 ) Property and equipment, net $ 2,497,856 $ 2,266,610 During the three months ended June 30, 2024, the Company recorded a non-cash property impairment charge of $ 1.0 million related to certain closed facilities, which is included in loss on impairment in the condensed consolidated statements of income. During the three months ended June 30, 2023, the Company recorded a non-cash property impairment charge of $ 2.0 million and a non-cash operating lease right-of-use asset impairment charge of $ 2.0 million related to the closure of certain facilities, which is included in loss on impairment in the condensed consolidated statements of income. The Company has recorded assets held for sale within other current assets on the consolidated balance sheets for closed properties actively marketed of $ 11.9 million and $ 11.5 million at June 30, 2024 and December 31, 2023 , respectively.

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill And Intangible Assets Disclosure [Abstract]
Other Identifiable Intangible Assets and Related Accumulated Amortization	Other identifiable intangible assets and related accumulated amortization consisted of the following (in thousands): Gross Carrying Amount Accumulated Amortization June 30, December 31, June 30, December 31, Intangible assets subject to amortization: Non-compete agreements $ 1,131 $ 1,131 $ ( 1,131 ) $ ( 1,131 ) Intangible assets not subject to amortization: Licenses and accreditations 11,688 11,681 — — Trade names 42,588 42,588 — — Certificates of need 19,072 19,009 — — 73,348 73,278 — — Total $ 74,479 $ 74,409 $ ( 1,131 ) $ ( 1,131 )

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Other Liabilities Disclosure [Abstract]
Summary of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued expenses $ 69,364 $ 80,733 Insurance liability – current portion 41,986 12,486 Accrued interest 18,158 18,046 Accrued property taxes 9,539 7,097 Cost report payable 4,293 9,265 Contract liabilities 1,801 2,165 Finance lease liabilities 990 990 Accrued Desert Hills settlement — 393,696 Other 12,784 7,783 Other accrued liabilities $ 158,915 $ 532,261

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consisted of the following (in thousands): June 30, December 31, Credit Facility: Term Loan A $ 701,583 $ 377,188 Revolving Line of Credit 225,000 80,000 5.500 % Senior Notes due 2028 450,000 450,000 5.000 % Senior Notes due 2029 475,000 475,000 Less: unamortized debt issuance costs, discount and ( 10,453 ) ( 10,421 ) 1,841,130 1,371,767 Less: current portion ( 66,574 ) ( 29,219 ) Long-term debt $ 1,774,556 $ 1,342,548

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Summary of Redeemable Noncontrolling Interests	The components of redeemable noncontrolling interests are as follows (in thousands): Balance at January 1, 2023 $ 88,257 Contributions from noncontrolling partners in joint ventures 16,530 Net income attributable to noncontrolling interests 6,006 Distributions to noncontrolling partners in joint ventures ( 5,107 ) Balance at December 31, 2023 105,686 Contributions from noncontrolling partners in joint ventures 2,970 Net income attributable to noncontrolling interests 4,722 Distributions to noncontrolling partners in joint ventures ( 1,500 ) Balance at June 30, 2024 $ 111,878

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2024
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Consolidated VIEs Assets and Liabilities	The consolidated VIEs assets and liabilities in the Company’s condensed consolidated balance sheets are shown below (in thousands): June 30, December 31, Cash and cash equivalents $ 74,099 $ 55,149 Accounts receivable, net 40,026 34,910 Other current assets 2,407 2,193 Total current assets 116,532 92,252 Property and equipment, net 541,961 438,965 Goodwill 42,384 42,384 Intangible assets, net 18,333 18,295 Operating lease right-of-use assets 10,064 5,948 Total assets $ 729,274 $ 597,844 Accounts payable $ 10,322 $ 8,235 Accrued salaries and benefits 9,990 9,909 Current portion of operating lease liabilities 573 273 Other accrued liabilities 2,444 2,385 Total current liabilities 23,329 20,802 Operating lease liabilities 10,056 6,160 Total liabilities $ 33,385 $ 26,962

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	Stock option activity during 2023 and 2024 was as follows: Number Weighted Weighted Aggregate Options outstanding at January 1, 2023 979,277 $ 46.27 Options granted 296,340 78.94 Options exercised ( 198,527 ) 41.29 Options cancelled ( 140,545 ) 55.95 Options outstanding at December 31, 2023 936,545 56.21 Options granted 3,000 78.59 Options exercised ( 121,468 ) 45.94 Options cancelled ( 45,560 ) 67.12 Options outstanding at June 30, 2024 772,517 $ 57.27 6.85 $ 10,819 Options exercisable at June 30, 2024 422,652 $ 48.06 5.80 $ 8,872
Schedule of Stock Options Valuation Assumptions	The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2024 and year ended December 31, 2023: June 30, December 31, Weighted average grant-date fair value of options $ 28.34 $ 30.99 Risk-free interest rate 4.4 % 4.2 % Expected volatility 33 % 37 % Expected life (in years) 4.7 5.0
Restricted Stock Activity	Restricted stock unit activity during 2023 and 2024 was as follows: Number of Weighted Unvested at January 1, 2023 1,045,202 $ 54.89 Granted 587,239 76.32 Cancelled ( 198,740 ) 57.21 Vested ( 403,223 ) 50.48 Unvested at December 31, 2023 1,030,478 $ 68.38 Granted 492,602 76.45 Cancelled ( 61,121 ) 70.45 Vested ( 287,340 ) 61.41 Unvested at June 30, 2024 1,174,619 $ 73.36
Performance stock unit activity	Performance stock unit activity during 2023 and 2024 was as follows: Number of Weighted Unvested at January 1, 2023 1,273,800 $ 20.69 Granted 177,509 70.98 Performance adjustment 407,825 17.69 Cancelled ( 114,908 ) 69.07 Vested ( 1,408,195 ) 10.60 Unvested at December 31, 2023 336,031 $ 69.35 Granted 75,909 67.85 Performance adjustment ( 9,241 ) 72.99 Cancelled ( 15,723 ) 70.37 Vested ( 98,504 ) 61.52 Unvested at June 30, 2024 288,472 $ 71.45

Transaction, Legal and Other _2

Transaction, Legal and Other Costs (Tables)	6 Months Ended
	Jun. 30, 2024
Transaction, Legal and Other Costs [Abstract]
Transaction, Legal and Other Costs as Incurred	Transaction, legal and other costs comprised the following costs for the three and six months ended June 30, 2024 and 2023 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Legal, accounting and other acquisition-related costs $ 4,085 $ 925 $ 9,323 2,564 Termination and restructuring costs 1,419 1,974 ( 1,981 ) 2,005 Management transition costs 587 6,175 $ 1,596 $ 10,976 $ 6,091 $ 9,074 $ 8,938 $ 15,545

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Carrying Amounts and Fair Values of Credit Facilities and Contingent Consideration Liabilities	The carrying amounts and fair values of the Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes at June 30, 2024 and December 31, 2023 were as follows (in thousands): Carrying Amount Fair Value June 30, December 31, June 30, December 31, Credit Facility $ 924,417 $ 455,880 $ 924,417 $ 455,880 5.500% Senior Notes due 2028 $ 445,981 $ 445,539 $ 435,946 $ 436,628 5.000% Senior Notes due 2029 $ 470,732 $ 470,348 $ 446,607 $ 451,534

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024 Bed State Facility
Accounting Policies [Abstract]
Number of facilities | Facility	258
Number of beds | Bed	11,400
Number of operating states | State	38

Revenue - Schedule of Revenue A

Revenue - Schedule of Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 796,040	$ 731,337	$ 1,564,091	$ 1,435,604
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	796,040	731,337	1,564,091	1,435,604
U.S. Facilities [Member] | Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	423,383	369,415	829,805	731,226
U.S. Facilities [Member] | Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	151,049	156,908	294,881	304,211
U.S. Facilities [Member] | Comprehensive Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	134,643	123,472	266,810	238,973
U.S. Facilities [Member] | Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 86,965	$ 81,542	$ 172,595	$ 161,194

Revenue - Schedule of Revenue_2

Revenue - Schedule of Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 796,040	$ 731,337	$ 1,564,091	$ 1,435,604
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 796,040	$ 731,337	$ 1,564,091	$ 1,435,604
Revenue, Percentage	100%	100%	100%	100%
U.S. Facilities [Member] | Commercial [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 209,636	$ 209,383	$ 405,653	$ 413,002
Revenue, Percentage	26.30%	28.60%	25.90%	28.80%
U.S. Facilities [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 111,708	$ 109,845	$ 221,096	$ 218,485
Revenue, Percentage	14%	15%	14.10%	15.20%
U.S. Facilities [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 452,338	$ 391,963	$ 888,760	$ 756,269
Revenue, Percentage	56.90%	53.60%	56.90%	52.70%
U.S. Facilities [Member] | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 13,513	$ 15,804	$ 29,940	$ 36,502
Revenue, Percentage	1.70%	2.20%	1.90%	2.50%
U.S. Facilities [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 8,845	$ 4,342	$ 18,642	$ 11,346
Revenue, Percentage	1.10%	0.60%	1.20%	0.80%

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$ 78,482	$ 76,383	$ 57,729	$ (217,710)	$ 72,299	$ 66,015	$ 154,865	$ 138,314
Denominator:
Weighted average shares outstanding for basic earnings per share	91,628				91,044		91,495	90,691
Effects of dilutive instruments	415				502		556	949
Shares used in computing diluted earnings per common share	92,043				91,546		92,051	91,640
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.86				$ 0.79		$ 1.69	$ 1.53
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Diluted	$ 0.85				$ 0.79		$ 1.68	$ 1.51

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.8	0.6	0.6	0.5

Acquisitions - Summary of chang

Acquisitions - Summary of changes in goodwill (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Business Combinations [Abstract]
Goodwill balance	$ 2,225,962	$ 2,222,805
Increase from acquisitions	35,433	337
Increase from contributions of redeemable noncontrolling interests		2,820
Goodwill balance	$ 2,261,395	$ 2,225,962

Other Current Assets - Other Cu

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Insurance receivable – current portion	$ 54,096	$ 33,579
Income taxes receivable	37,133	12,416
Prepaid expenses	31,930	36,085
Other receivables	24,005	22,084
Workers’ compensation deposits – current portion	12,000	12,000
Assets held for sale	11,865	11,496
Inventory	5,988	5,300
Other	1,656	1,516
Other current assets	$ 178,673	$ 134,476

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,329,808	$ 3,033,956
Less: accumulated depreciation	(831,952)	(767,346)
Property and equipment, net	2,497,856	2,266,610
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	195,759	183,347
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,105,463	2,064,353
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	402,307	365,826
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 626,279	$ 420,430

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Loss on Impairment [Member]
Property Plant And Equipment [Line Items]
Non-cash property impairment charge relating to closure of facilities	$ 1	$ 2
Non-cash operating lease right-of-use asset impairment charge related to closure of facilities		$ 2
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale	$ 11.9		$ 11.5

Other Intangible Assets - Other

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 73,348	$ 73,278
Total	74,479	74,409
Total	(1,131)	(1,131)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	(1,131)	(1,131)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	11,688	11,681
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	42,588	42,588
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 19,072	$ 19,009

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Details) $ in Millions	3 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Non-cash indefinite-lived intangible asset impairment charge	$ 4.7

The CARES Act - Additional Info

The CARES Act - Additional Information (Detail) - CARES Act [Member] - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
CARES Act [Line Items]
Offer of eligible relief amount	$ 100,000
American Rescue Plan
CARES Act [Line Items]
Income from relief fund		$ 6.4

Other Accrued Liabilities - Sum

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued expenses	$ 69,364	$ 80,733
Insurance liability – current portion	41,986	12,486
Accrued interest	18,158	18,046
Accrued property taxes	9,539	7,097
Cost report payable	4,293	9,265
Contract liabilities	1,801	2,165
Finance lease liabilities	$ 990	$ 990
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities	Other accrued liabilities
Accrued Desert Hills settlement		$ 393,696
Other	$ 12,784	7,783
Other accrued liabilities	$ 158,915	$ 532,261

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Mar. 17, 2021
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (10,453)	$ (10,421)
Long-term debt	1,841,130	1,371,767
Less: current portion	(66,574)	(29,219)
Long-term debt	1,774,556	1,342,548
Credit Facility [Member] | Term Loan A [Member]
Debt Instrument [Line Items]
Revolving Facility	701,583	377,188
Credit Facility [Member] | Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Revolving Facility	225,000	80,000	$ 600,000
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Senior Notes	450,000	450,000
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 475,000	$ 475,000

Long-Term Debt - Components o_2

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Oct. 14, 2020	Jun. 24, 2020
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
Senior notes maturity year	2028	2028
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5%	5%	5%
Senior notes maturity year	2029	2029

Long-Term Debt (Credit Facility

Long-Term Debt (Credit Facility) - Additional Information (Detail) - USD ($)				6 Months Ended
	Jan. 18, 2024	Mar. 30, 2023	Mar. 17, 2021	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Repayments of revolving facility				$ 15,000,000	$ 20,000,000
Credit Facility [Member]
Debt Instrument [Line Items]
Amount available under revolving line of credit				371,500,000
Repayments of revolving facility				15,000,000	20,000,000
Borrowings on revolving credit facility				$ 160,000,000	$ 40,000,000
Term loan remaining balance due date	Mar. 17, 2026
Maximum incremental debt amount						$ 480,000,000
Incremental debt amount maximum percentage of consolidated EBITDA				100%
Consolidated senior secured net leverage ratio				3.50%
Maximum consolidated net leverage ratio				4.50%
Increased consolidated net leverage ratio				5%
Minimum interest coverage ratio				3%
Credit Facility [Member] | SOFR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		0.10%
Credit Facility [Member] | September 30, 2024 to March 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	$ 15,400,000
Credit Facility [Member] | June 30, 2025 to December 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	20,500,000
Credit Facility [Member] | Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount			$ 600,000,000	$ 225,000,000		80,000,000
Credit Facility [Member] | Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount				701,583,000		$ 377,188,000
Debt instrument maturity date			Mar. 17, 2026
Credit Facility [Member] | Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount			$ 20,000,000
Credit Facility [Member] | Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount				$ 3,500,000
Credit Facility [Member] | Incremental Term Loans [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	425,000,000		$ 425,000,000
Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Unused fee payable percentage		0.35%
Credit Facility [Member] | Maximum [Member] | SOFR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%
Credit Facility [Member] | Maximum [Member] | Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		1.25%
Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Unused fee payable percentage		0.20%
Credit Facility [Member] | Minimum [Member] | SOFR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		1.375%
Credit Facility [Member] | Minimum [Member] | Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		0.375%
Credit Facility [Member] | First Amemdment [Member] | Incremental Term Loans [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 350,000,000

Long-Term Debt (5.500% Senior N

Long-Term Debt (5.500% Senior Notes due 2028) - Additional Information (Detail) - 5.500% Senior Notes due 2028 [Member] - USD ($) $ in Millions		6 Months Ended
	Jun. 24, 2020	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Issued Senior Notes	$ 450
Debt instrument interest rate	5.50%	5.50%	5.50%
Debt instrument maturity date	Jul. 01, 2028
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021

Long-Term Debt (5.000% Senior N

Long-Term Debt (5.000% Senior Notes due 2029) - Additional Information (Detail) - 5.000% Senior Notes due 2029 [Member] - USD ($) $ in Millions		6 Months Ended
	Oct. 14, 2020	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Issued Senior Notes	$ 475
Debt instrument interest rate	5%	5%	5%
Debt instrument maturity date	Apr. 15, 2029
Interest on the notes		payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021.

Noncontrolling Interests - Addi

Noncontrolling Interests - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	10
Non-Wholly Owned Subsidiaries [Member] | Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	65%
Non-Wholly Owned Subsidiaries [Member] | Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	87%

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Noncontrolling Interest [Abstract]
Beginning Balance	$ 105,686	$ 88,257
Contributions from noncontrolling partners in joint ventures	2,970	16,530
Net income attributable to noncontrolling interests	4,722	6,006
Distributions to noncontrolling partners in joint ventures	(1,500)	(5,107)
Ending Balance	$ 111,878	$ 105,686

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) Facility	Dec. 31, 2023 USD ($)
Variable Interest Entity [Line Items]
Consolidated assets	$ 5,678,052	$ 5,358,841
Consolidated liabilities	$ 2,613,456	2,471,181
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of facilities operated through non-wholly owned subsidiaries | Facility	10
Consolidated assets	$ 729,274	597,844
Consolidated liabilities	$ 33,385	$ 26,962
Variable Interest Entity, Primary Beneficiary [Member] | Minimum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	65%
Variable Interest Entity, Primary Beneficiary [Member] | Maximum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	87%

Variable Interest Entities - Sc

Variable Interest Entities - Schedule of Consolidated VIEs Assets and Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 77,167	$ 100,073
Accounts receivable, net	389,374	361,451
Other current assets	178,673	134,476
Total current assets	645,214	596,000
Property and equipment, net	2,497,856	2,266,610
Goodwill	2,261,395	2,225,962	$ 2,222,805
Intangible assets, net	73,348	73,278
Operating lease right-of-use assets	123,273	117,780
Total assets	5,678,052	5,358,841
Accounts payable	159,520	156,132
Accrued salaries and benefits	134,503	141,901
Current portion of operating lease liabilities	27,010	26,268
Other accrued liabilities	158,915	532,261
Total current liabilities	546,522	885,781
Operating lease liabilities	104,706	100,808
Other liabilities	150,641	140,113
Total liabilities	2,613,456	2,471,181
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	74,099	55,149
Accounts receivable, net	40,026	34,910
Other current assets	2,407	2,193
Total current assets	116,532	92,252
Property and equipment, net	541,961	438,965
Goodwill	42,384	42,384
Intangible assets, net	18,333	18,295
Operating lease right-of-use assets	10,064	5,948
Total assets	729,274	597,844
Accounts payable	10,322	8,235
Accrued salaries and benefits	9,990	9,909
Current portion of operating lease liabilities	573	273
Other accrued liabilities	2,444	2,385
Total current liabilities	23,329	20,802
Operating lease liabilities	10,056	6,160
Total liabilities	$ 33,385	$ 26,962

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	12,700,000		12,700,000
Equity incentive plan available for future grant	2,068,284		2,068,284
Stock options, contractual term			10 years
Equity-based compensation expense	$ 8,869	$ 7,348	$ 17,547	$ 14,977
Unrecognized compensation expense related to unvested options			$ 89,100
Vesting period			1 year 3 months 18 days
Deferred income tax benefit			$ 39,017	347
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increments in employee grants			25%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increments in employee grants			33%
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 2,400	$ 2,000	$ 4,800	$ 4,100
Restricted Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Performance Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issuable at the end of the vesting period, percentage			0%
Performance Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issuable at the end of the vesting period, percentage			200%

Equity-Based Compensation - Sto

Equity-Based Compensation - Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance | shares	936,545	979,277
Options granted | shares	3,000	296,340
Options exercised | shares	(121,468)	(198,527)
Options cancelled | shares	(45,560)	(140,545)
Options outstanding, Ending balance | shares	772,517	936,545
Options exercisable, Ending balance | shares	422,652
Options outstanding, Weighted Average Exercise Price, Beginning balance | $ / shares	$ 56.21	$ 46.27
Options granted, Weighted Average Exercise Price | $ / shares	78.59	78.94
Options exercised, Weighted Average Exercise Price | $ / shares	45.94	41.29
Options cancelled, Weighted Average Exercise Price | $ / shares	67.12	55.95
Options outstanding, Weighted Average Exercise Price, Ending balance | $ / shares	57.27	$ 56.21
Options exercisable, Weighted Average Exercise Price, Ending balance | $ / shares	$ 48.06
Options outstanding, Weighted Average Remaining Contractual Term	6 years 10 months 6 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	5 years 9 months 18 days
Options outstanding, Aggregate Intrinsic Value | $	$ 10,819
Options exercisable, Aggregate Intrinsic Value, Ending balance | $	$ 8,872

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 28.34	$ 30.99
Risk-free interest rate	4.40%	4.20%
Expected volatility	33%	37%
Expected life (in years)	4 years 8 months 12 days	5 years

Equity-Based Compensation - Res

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	1,030,478	1,045,202
Granted, Number of Shares	492,602	587,239
Cancelled, Number of Shares	(61,121)	(198,740)
Vested, Number of Shares	(287,340)	(403,223)
Unvested, Number of Shares/Units, Ending balance	1,174,619	1,030,478
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 68.38	$ 54.89
Granted, Weighted Average Grant-Date Fair Value	76.45	76.32
Cancelled, Weighted Average Grant-Date Fair Value	70.45	57.21
Vested, Weighted Average Grant-Date Fair Value	61.41	50.48
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 73.36	$ 68.38

Equity-Based Compensation - Per

Equity-Based Compensation - Performance Stock Unit Activity (Detail) - Performance Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	336,031	1,273,800
Granted, Number of Units	75,909	177,509
Performance adjustment, Number of Units	(9,241)	407,825
Cancelled, Number of Units	(15,723)	(114,908)
Vested, Number of Units	(98,504)	(1,408,195)
Unvested, Number of Shares/Units, Ending balance	288,472	336,031
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 69.35	$ 20.69
Granted, Weighted Average Grant-Date Fair Value	67.85	70.98
Performance adjustment, Weighted Average Grant-Date Fair Value	72.99	17.69
Cancelled, Weighted Average Grant-Date Fair Value	70.37	69.07
Vested, Weighted Average Grant-Date Fair Value	61.52	10.6
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 71.45	$ 69.35

Transaction, Legal and Other _3

Transaction, Legal and Other Costs - Transaction, Legal and Other Costs as Incurred (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Transaction, Legal and Other Costs [Abstract]
Legal, accounting and other acquisition-related costs	$ 4,085	$ 925	$ 9,323	$ 2,564
Termination and restructuring costs	1,419	1,974	(1,981)	2,005
Management transition costs	587	6,175	1,596	10,976
Transaction, legal and other costs	$ 6,091	$ 9,074	$ 8,938	$ 15,545

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Effective tax rates	24.10%	23.70%	22.30%	23%

Fair Value Measurements - Carry

Fair Value Measurements - Carrying Amounts and Fair Values of Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Carrying Amount [Member] | Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Revolving Facility	$ 924,417	$ 455,880
Carrying Amount [Member] | 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	445,981	445,539
Carrying Amount [Member] | 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	470,732	470,348
Fair Value [Member] | Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	924,417	455,880
Fair Value [Member] | 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	435,946	436,628
Fair Value [Member] | 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 446,607	$ 451,534

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	Jun. 30, 2024	Dec. 31, 2023	Oct. 14, 2020	Jun. 24, 2020
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5%	5%	5%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)			1 Months Ended	6 Months Ended
	Jan. 19, 2024	Jul. 07, 2023	Aug. 31, 2023	Jun. 30, 2024
Loss Contingencies [Line Items]
Aggregate amount on settlement agreements	$ 400,000,000
Anticipated financial impact value				$ 19,900,000
Inman Litigation [Member] | Compensatory Damages [Member]
Loss Contingencies [Line Items]
Awarded plaintiff damages amount		$ 80,000,000
Inman Litigation [Member] | Punitive Damages [Member]
Loss Contingencies [Line Items]
Awarded plaintiff damages amount		$ 405,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Maximum coverage limit per claim			$ 5,000,000	7,000,000
Reinsurance policy aggregate policy limit			75,000,000	78,000,000
Minimum [Member]
Loss Contingencies [Line Items]
Maximum professional liability for certain other claims thereafter			10,000,000	10,000,000
Reinsurance policy aggregate policy limit			$ 70,000,000	$ 75,000,000